MCID: PDT001
MIFTS: 45

Pediatric Lymphoma

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Pediatric Lymphoma

MalaCards integrated aliases for Pediatric Lymphoma:

Name: Pediatric Lymphoma 12 15
Childhood Lymphoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5823
NCIt 50 C5165
UMLS 73 C1332979

Summaries for Pediatric Lymphoma

MalaCards based summary : Pediatric Lymphoma, also known as childhood lymphoma, is related to hemangioma of spleen and gallbladder small cell carcinoma. An important gene associated with Pediatric Lymphoma is DAPK1 (Death Associated Protein Kinase 1), and among its related pathways/superpathways are NF-kappaB Signaling and Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. The drugs Teniposide and rituximab have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Pediatric Lymphoma

Diseases related to Pediatric Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 hemangioma of spleen 10.9 CD9 SMUG1
2 gallbladder small cell carcinoma 10.8 NCAM1 SMUG1
3 bone lymphoma 10.8 CD22 SMUG1
4 renal adenoma 10.7 B3GAT1 NCAM1
5 breast lymphoma 10.7 ALK SMUG1
6 epithelial predominant wilms' tumor 10.7 B3GAT1 NCAM1
7 transient neonatal neutropenia 10.6 FCGR3A FCGR3B
8 lung combined type small cell carcinoma 10.6 MME NCAM1
9 extrahepatic bile duct adenocarcinoma 10.6 MME NCAM1
10 tibial adamantinoma 10.5 CD34 SMUG1
11 viral infectious disease 10.5 CD81 IRF3 IRF7
12 spleen angiosarcoma 10.4 CD34 SMUG1
13 breast leiomyosarcoma 10.4 CD34 SMUG1
14 bone epithelioid hemangioma 10.4 CD34 SMUG1
15 endometrial small cell carcinoma 10.4 NCAM1 SMUG1
16 lung meningioma 10.4 CD34 NCAM1
17 spastic paraplegia 32, autosomal recessive 10.4 B3GAT1 FCGR3A FCGR3B
18 extraosseous osteosarcoma 10.4 CD34 SMUG1
19 diffuse infiltrative lymphocytosis syndrome 10.3 B3GAT1 FCGR3A FCGR3B
20 parasitic ichthyosporea infectious disease 10.3 NCAM1 RHOJ
21 eccrine adenocarcinoma 10.3 CD34 SMUG1
22 granulomatous myositis 10.3 NCAM1 SMUG1 TNFRSF8
23 rhinosporidiosis 10.3 NCAM1 RHOJ
24 intravascular fasciitis 10.3 ALK CD34
25 hodgkin's lymphoma, lymphocytic depletion 10.2 ALK TNFRSF8
26 jejunal adenocarcinoma 10.2 MSH6 SMUG1
27 t-cell adult acute lymphocytic leukemia 10.2 CD34 MME
28 breast myofibroblastoma 10.2 CD34 MME
29 conventional angiosarcoma 10.2 CD34 NCAM1
30 lymphoma 10.2
31 malignant leydig cell tumor 10.2 MME TNFRSF8
32 invasive malignant thymoma 10.1 CD34 MME
33 t-cell/histiocyte rich large b cell lymphoma 10.1 MME TNFRSF8
34 psammomatous meningioma 10.1 CD34 MME
35 ovarian solid teratoma 10.1 CD34 TNFRSF8
36 chronic nk-cell lymphocytosis 10.1 B3GAT1 FCGR3A FCGR3B NCAM1
37 gastrointestinal system cancer 10.1 CD34 MSH6 SMUG1
38 plexiform schwannoma 10.1 B3GAT1 CD34
39 mediastinal cancer 10.1 NCAM1 SMUG1
40 venous hemangioma 10.0 CD34 KLF4
41 paraphimosis 10.0 CD34 TNFRSF8
42 cell type cancer 10.0 ALK CD34 SMUG1
43 peripheral nervous system neoplasm 10.0 ALK CD34 NCAM1
44 orbital plasma cell granuloma 9.9 FCGR3A FCGR3B MME NCAM1
45 chronic orbital inflammation 9.9 FCGR3A FCGR3B MME NCAM1
46 sternum cancer 9.9 CD34 SMUG1 TNFRSF8
47 adult lymphoma 9.8 ALK FCGR3A SMUG1 TNFRSF8
48 colon lymphoma 9.7 ALK CD22 MSH6 TNFRSF8
49 diffuse large b-cell lymphoma 9.7 ALK MME TNFRSF8
50 conventional fibrosarcoma 9.7 CD34 TNFRSF8

Graphical network of the top 20 diseases related to Pediatric Lymphoma:



Diseases related to Pediatric Lymphoma

Symptoms & Phenotypes for Pediatric Lymphoma

MGI Mouse Phenotypes related to Pediatric Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CD22 CD34 CD81 CD9 DAP DNTT
2 homeostasis/metabolism MP:0005376 10 FCGR3B IRF3 IRF7 KLF4 MME MSH6
3 immune system MP:0005387 9.77 CD22 CD34 CD81 CD9 DAP DNTT
4 neoplasm MP:0002006 9.1 ALK CD34 KLF4 MSH6 RHOJ SMUG1

Drugs & Therapeutics for Pediatric Lymphoma

Drugs for Pediatric Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 962)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
3
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
8
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
9
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
13
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
14
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
15
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
16
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
17
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
18
Tropisetron Approved, Investigational Phase 4,Not Applicable 105826-92-4, 89565-68-4 5595
19
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 7439-89-6 23925
20
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 151165 6918365
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
22
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
23
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3375-50-6 598
24
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
25
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
26
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
27
Zidovudine Approved Phase 4,Phase 2,Not Applicable 30516-87-1 35370
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
29
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
30
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
31
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
33
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
35
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
37
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
38
Palonosetron Approved, Investigational Phase 4,Phase 2,Not Applicable 135729-61-2, 119904-90-4, 135729-56-5 148211
39
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
41
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
42
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
43
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
44
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
45
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
46
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
47
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
48
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
49
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
50
Granisetron Approved, Investigational Phase 4,Phase 2,Not Applicable 109889-09-0 3510

Interventional clinical trials:

(show top 50) (show all 6498)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
6 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
12 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
13 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
14 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
15 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
16 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
17 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
18 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
19 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
20 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
21 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
22 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
23 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
24 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
25 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
26 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
27 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
28 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
29 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
30 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
31 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
32 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
33 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
34 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
35 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
36 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
37 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
38 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
39 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
40 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
41 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
42 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
43 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
44 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
45 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
46 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
47 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
48 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
49 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
50 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa

Search NIH Clinical Center for Pediatric Lymphoma

Genetic Tests for Pediatric Lymphoma

Anatomical Context for Pediatric Lymphoma

MalaCards organs/tissues related to Pediatric Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lung, Myeloid, Nk Cells

Publications for Pediatric Lymphoma

Articles related to Pediatric Lymphoma:

(show all 30)
# Title Authors Year
1
Pharmacotherapeutic Management of Pediatric Lymphoma. ( 29127674 )
2018
2
Pediatric Lymphoma. ( 28864732 )
2017
3
A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma. ( 27313888 )
2016
4
Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. ( 26901021 )
2016
5
Comparison of 11C-methionine and 18F-FDG PET-CT for staging and follow-up of pediatric lymphoma. ( 27609791 )
2016
6
Socioeconomic Factors Impact Inpatient Mortality in Pediatric Lymphoma Patients. ( 27433403 )
2016
7
Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. ( 27003132 )
2016
8
Imaging of primary pediatric lymphoma of bone. ( 27043729 )
2016
9
Emerging immunotherapy in pediatric lymphoma. ( 26616565 )
2016
10
Treatment of pediatric lymphoma in Japan: Current status and plans for the future. ( 26096060 )
2015
11
Pediatric lymphoma diagnosis: role of FNAC, biopsy, immunohistochemistry and molecular diagnostics. ( 23925793 )
2013
12
Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation. ( 22033780 )
2012
13
Role of limited whole-body PET/CT in pediatric lymphoma. ( 21512070 )
2011
14
Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. ( 21505896 )
2011
15
Presence of human herpes virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection. ( 20979645 )
2010
16
Intussusception incidentally detected by FDG-PET/CT in a pediatric lymphoma patient. ( 20449693 )
2010
17
Role of PET/CT in malignant pediatric lymphoma. ( 19756591 )
2010
18
Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan. ( 20051771 )
2010
19
Methodological issues in the evaluation of FDG PET/CT accuracy in pediatric lymphoma. ( 20821007 )
2010
20
Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use? ( 20224437 )
2010
21
Compound heterozygosity for MSH6 mutations in a pediatric lymphoma patient. ( 19194194 )
2009
22
FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients. ( 27156825 )
2008
23
Stem cell transplantation for pediatric lymphoma: past, present and future. ( 18084337 )
2008
24
The accuracy of PET(CT) in evaluating pediatric lymphoma. ( 17805051 )
2007
25
Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. ( 17454627 )
2007
26
Pulmonary involvement in pediatric lymphoma. ( 14605781 )
2004
27
Epigenetic changes in the DAP-kinase CpG island in pediatric lymphoma. ( 14595709 )
2003
28
Disturbances in oral and dental structures in patients with pediatric lymphoma after chemotherapy: a preliminary report. ( 10102592 )
1999
29
MIC2 analysis in pediatric lymphomas and leukemias. ( 8163272 )
1994
30
An unusual pediatric lymphoma. ( 1513898 )
1992

Variations for Pediatric Lymphoma

Expression for Pediatric Lymphoma

Search GEO for disease gene expression data for Pediatric Lymphoma.

Pathways for Pediatric Lymphoma

GO Terms for Pediatric Lymphoma

Cellular components related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 ALK CD22 CD34 CD81 CD9 DAPK1
2 extracellular exosome GO:0070062 9.32 ALK CD22 CD81 CD9 FCGR3A FCGR3B
3 external side of plasma membrane GO:0009897 9.26 CD34 CD9 FCGR3A NCAM1

Biological processes related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic signaling pathway GO:0097190 9.58 DAP DAPK1 TNFRSF8
2 regulation of immune response GO:0050776 9.56 CD34 CD81 FCGR3A IRF7
3 viral process GO:0016032 9.55 CD81 IRF3 IRF7 MSH6 NCAM1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.5 IRF3 IRF7 NCAM1
5 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.48 CD81 CD9
6 regulation of type I interferon production GO:0032479 9.46 IRF3 IRF7
7 positive regulation of interferon-alpha production GO:0032727 9.43 IRF3 IRF7
8 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.37 IRF3 IRF7
9 type I interferon biosynthetic process GO:0045351 8.96 IRF3 IRF7
10 MDA-5 signaling pathway GO:0039530 8.62 IRF3 IRF7

Molecular functions related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.62 FCGR3A FCGR3B

Sources for Pediatric Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....